The Efficacy of Chinese Herbal Medicine as an Adjunctive Therapy for Advanced Non-small Cell Lung Cancer: A Systematic Review and Meta-analysis

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Li, Shi Guang ^a,b   Chen, Hai Yong ^c   Ou Yang, Chen Sheng ^a,b   Wang, Xi Xin ^d   Yang, Zhen Jiang ^a,b   Tong, Yao ^c   Cho, William C S ^e  

^a GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

^b Shenzhen Hospital of Traditional Chinese Medicine   (China)

^c THE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Shanxi Province Hospital of Traditional Chinese Medicine   (China)

^e QUEEN ELIZABETH HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FEIJI; FEITAI; FEIYAN NING; FUZHENG JIEDU; FUZHENG KANGAI; GEMCITABINE; HAISHENSU; HECHAN PIAN; HERBACEOUS AGENT; JIANPI YANGXUE; KANGLIU ZENGXIAO; MEIHUA DIANSHE; MITOMYCIN; NAVELBINE; PACLITAXEL; SHENGMAI; SHENMAI; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINDESINE; XIAOJI; YANGYIN RUANJIAN; YANSHU; YINQI YANGYIN; ZIYIN QINRE JIEDU;

ADJUVANT THERAPY; ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHINESE MEDICINE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEMOGLOBIN BLOOD LEVEL; HUMAN; KARNOFSKY PERFORMANCE STATUS; LEUKOCYTE COUNT; LUNG NON SMALL CELL CANCER; META ANALYSIS; NAUSEA AND VOMITING; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW; THROMBOCYTE COUNT;

ADJUVANTS, PHARMACEUTIC; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; DRUGS, CHINESE HERBAL; HUMANS; LUNG NEOPLASMS; TREATMENT OUTCOME;

EID: 84874572641     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057604     Document Type: Article

References (64)

1. Siegel R, Naishadham D, Jemal A, (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, et al. (2004) American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22: 330-353.
3. Azzoli CG, Temin S, Aliff T, Baker S Jr, Brahmer J, et al. (2011) 2011 Focused update of 2009 American Society of Clinical Oncology Clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 29: 3825-3831.
4. Arriagada R, Dunant A, Pignon JP, Bergman B, Chabowski M, et al. (2010) Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol 28: 35-42.
5. Kato H, Tsuboi M, Kato Y, Ikeda N, Okunaka T, et al. (2005) Postoperative adjuvant therapy for completely resected early-stage non-small cell lung cancer. Int J Clin Oncol 10: 157-164.
6. Gkiozos I, Charpidou A, Syrigos K, (2007) Developments in the treatment of non-small cell lung cancer. Anticancer Res 27: 2823-2827.
7. Baggstrom MQ, Stinchcombe TE, Fried DB, Poole C, Hensing TA, et al. (2007) Third-generation chemotherapy agents in the treatment of advanced non-small cell lung cancer: a meta-analysis. J Thorac Oncol 2: 845-853.
8. Chen YZ, Li ZD, Gao F, Zhang Y, Sun H, et al. (2009) Effects of combined Chinese drugs and chemotherapy in treating advanced non-small cell lung cancer. Chin J Integr Med 15: 415-419.
9. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12.
10. Huang C, Liao TH, (2008) Effect of combination of Chenxialiujun decoction and chemotherapy on non-small lung cell cancer. Hebei J Tradit Chin Med 30: 1287-1288.
11. Liang QL, Zhang Y, Xie JR, Li SJ, Luo HQ, et al. (2007) Clillical study on effcacy of compound Dashen droplet pill with chemotherapy in treating advanced non-small cell lung cancer. Shanghai J Tradit Chin Med 41: 22-24.
12. Qi YF, Li XR, Li HJ, (2011) Clinical study on lung cancer treated by Dahuang Zhechong Wan. Chin J Inf Tradit Chin Med 18: 15-17.
13. Yan GY, Xu ZY, Deng HB, Wan ZY, Zhang L, et al. (2011) Effect s of chemotherapy combined with Chinese herbal medicine Kangliu Zengxiao decoction on tumor markers of patient s with advanced non-small cell lung cancer: a randomized, controlled trial. J Chin Integr Med 9: 525-530.
14. Yang PY, Jia YJ, Chen J, Li XJ, Sun YY, et al. (2011) A clinical study of Xiao-yan decoction combined with chemotherapy on the immune function of the NSCLC patients with "Qi deficiency and blood statsis". J New Chin Med 43: 64-65.
15. Wang YC, Zhang RH, (2009) Clinical effect of non-small cell lung cancer treated by combined chemotherapy with Zhongliuan capsule. Chin Tradit Patent Med 31: 669-673.
16. Chen Y, Di L, Zhang S, Chen M, Sun H, et al. (2008) The randomized, multicenter, controlled clinic trail for treating advanced non-small cell lung cancer with combined traditional chinese medicine and vinorelbine (Navelbine, NVB) plus cisplatin (DDP) chemotherapy. Zhongguo Fei Ai Za Zhi 11: 441-444.
17. Chen XZ, Huang ZQ, Yang YL, Qian HQ, Liang GW, et al. (2011) The intervention effect of Feiji recipe on CD62P of non-small cell lung cancer patients. Chin Med Mod Distance Ed China 9: 93-95.
18. Li LN, Liu WS, Xu K, Wu WY, Liu YL, et al. (2003) The prognosis factors of comprehensive treatment with traditional Chinese medicine to non-small cell lung cancer. Shanxi Cancer Med 11: 44-47.
19. Lu XA, Wei YR, (2009) Therapeutic effect of combination of Shenmai injection and radio-chemotherapy on advanced non-small cell lung cancer. Hebei J Tradit Chin Med 31: 597-599.
20. Yang HL, (2007) Cost-effect analysis of integrated Chinese and Western medical treatment for advanced non-small cell lung cancer. J Tradit Chin Med 48: 232-234.
21. Zhang PT, Lin HS, Yu MW, Yang ZY, Dong HT, et al. (2012) Application of traditional Chinese medicine and Western medical therapeutic evaluation methodologies for the combination treatment with Feiliuping extract and chemotherapy in advanced non-small cell lung cancer. J Tradit Chin Med 53: 403-406.
22. Zhang Z, Yu SQ, Miao L, Huang XY, Zhang XP, et al. (2008) Artesunate combined with vinorelbline plus cisplatin in treatment of advanced non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 6: 134-138.
23. Deng S, Ouyang X, Yu Z, Dai X, Chen X, et al. (2012) Influence of Chinese herbal medicine Feitai capsule on completion or delay of chemotherapy in patients with stage IIIB/IV non-small cell lung cancer: a randomized controlled trial. Zhong Xi Yi Jie He Xue Bao 10: 635-640.
24. Huang YL, Hou AJ, Hu Y, Zhou L, Gao HF, (2011) The clinical effect of Yi Qi Yang Yin Chinese medicine combined with GP chemotherapy to the advanced non-small cell lung cancer patients. J New Chin Med 43: 47-49.
25. Huang YL, Hou AJ, Zhou L, Hu Y, Shen XY, (2012) Clinical study on non-small cell lung cancer treated by Zi Yin Qin Re herbs combined with chemotherapy. Liaoning Tradit Chin Med J 2: 53.
26. Li GY, Yu XM, Zhang HW, Zhang B, Wang CB, et al. (2009) Haishengsu as an adjunct therapy to conventional chemotherapy in patients with non-small cell lung cancer: a pilot randomized and placebo-controlled clinical trial. Complement Ther Med 17: 51-55.
27. Lin J, (2008) Clinical study on the combined Chinese and Western medicine in treating 58 cases of non-small cell lung cancer. Henan J Tradit Chin Med 28: 29-31.
28. Lin LZ, Zheng XT, (2011) Clinical observation of the therapeutic effect of traditional Chinese medicine in the treatment of elderly non-small cell lung cancer. Tradit Chin Drug Res Clin Pharmacol 22: 120-122.
29. Sun QS, (2011) Clinical observation of the therapeutic effect of chemotherapy plus traditional Chinese medicine in the treatment of advanced non-small cell lung cancer. Hainan Med J 22: 31-33.
30. Xu ZY, Jin CJ, Shen DY, Li M, Zhou WD, et al. (2007) Clinical study on treatment of advanced non-small cell lung cancer with Chinese herbal medicine in different stages combined with chemotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 27: 874-878.
31. Zheng QH, Liao XF, Wang Y (2010) Thirty cases of docetaxel plus cisplatin with Shenmai injection in treatment of advanced non-small cell lung cancer. Jiangxi J Tradit Chin Med 57-58.
32. Zhou DH, Lin LZ, Zhou YQ, Luo RC, LIu KF, et al. (2005) Cost-effectiveness analysis of three therapeutic regimens for advanced non-small cell lung cancer. Chin J Clin Oncol 32: 1081-1084.
33. Zhou L, Liu JX, Li HG, Zhao LH, Liu LS, et al. (2012) Comparative study on treatment of advance non-small cell lung cancer by two methods. Shanghai J Tradit Chin Med 5: 8.
34. Zhu LM, Guo JF, (2011) Clinical study of Yanshu injection on treating advanced non-small cell lung cancer. Chin J Clin Oncol Rehabil 18: 380-384.
35. Yao QB, Wang LX, Ni W, Shen YL, Zhu Y, et al. (2011) Clinical observation of "Yang Yin Ruan Jian" on non-small cell lung cancer. J Zhejiang Chin Med Uni 35: 501-503.
36. Zhu LM, Zhang H, Zhou H, Pan CF, Shen KP, et al. (2011) Time-effect relationship of Kangliu Zengxiao decoction in reducing chemotherapy associated adverse reactions in patients with advanced non-small cell lung cancer. J Shanghai Jiaotong Uni (Med Sci) 31: 797-801.
37. Zheng HG, Pu BK, Lin HS, Xiong L, Hua BJ, et al. (2007) The efficacy of Feiliuping decoction on dendritic cell subtypes and immune function in patients with non-small cell lung carcinoma. Beijing J Tradit Chin Med 26: 214-217.
38. Shan M, Han B, You J, (2011) Assessment of therapeutic efficacy on treating advanced non-small cell lung cancer in the aged by Chinese medicine adopting the international questionnaire of quality of life. Zhongguo Zhong Xi Yi Jie He Za Zhi 31: 873-879.
39. Li Y, Li C, (2012) Clinical study of treatment of cancer chemotherapy by Jianpi Yangxue Tang. Guangming J Chin Med 27: 108-109.
40. Hyodo I, Amano N, Eguchi K, Narabayashi M, Imanishi J, et al. (2005) Nationwide survey on complementary and alternative medicine in cancer patients in Japan. J Clin Oncol 23: 2645-2654.
41. Chang KH, Brodie R, Choong MA, Sweeney KJ, Kerin MJ, (2011) Complementary and alternative medicine use in oncology: a questionnaire survey of patients and health care professionals. BMC Cancer 11: 196.
42. Li JH, (1996) A study on treatment of lung cancer by combined therapy of traditional Chinese medicine and chemotherapy. Zhongguo Zhong Xi Yi Jie He Za Zhi 16: 136-138.
43. Bent S, (2008) Herbal medicine in the United States: review of efficacy, safety, and regulation: grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med 23: 854-859.
44. Cho WC, Chen HY, (2009) Transcatheter arterial chemoembolization combined with or without Chinese herbal therapy for hepatocellular carcinoma: meta-analysis. Expert Opin Investig Drugs 18: 617-635.
45. Cho WC, Chen HY, (2009) Clinical efficacy of traditional Chinese medicine as a concomitant therapy for nasopharyngeal carcinoma: a systematic review and meta-analysis. Cancer Invest 27: 334-344.
46. Zhong LL, Chen HY, Cho WC, Meng X, Tong Y, (2012) The efficacy of Chinese herbal medicine as an adjunctive therapy for colorectal cancer: a systematic review and meta-analysis. Complementary therapies in medicine. Complement Ther Med 20: 240-252.
47. Yates JS, Mustian KM, Morrow GR, Gillies LJ, Padmanaban D, et al. (2005) Prevalence of complementary and alternative medicine use in cancer patients during treatment. Supportive Care Cancer 13: 806-811.
48. Brake MK, Bartlett C, Hart RD, Trites JR, Taylor SM, (2011) Complementary and alternative medicine use in the thyroid patients of a head and neck practice. Otolaryngol Head Neck Surg 145: 208-212.
49. Chen S, Flower A, Ritchie A, Liu J, Molassiotis A, et al. (2010) Oral Chinese herbal medicine (CHM) as an adjuvant treatment during chemotherapy for non-small cell lung cancer: a systematic review. Lung Cancer 68: 137-145.
50. Dugoua JJ, Wu P, Seely D, Eyawo O, Mills E, (2010) Astragalus-containing Chinese herbal combinations for advanced non-small-cell lung cancer: a meta-analysis of 65 clinical trials enrolling 4751 patients. Lung Cancer 1: 85-100.
51. Li Y, Li C-H, Tang F-T, Li X-F, (2004) Pharmacological action of adenophora polysaccharides. Chin J Integr Med 10: 78-80.
52. Gupta S, Zhang D, Yi J, Shao J, (2004) Anticancer activities of Oldenlandia diffusa. J Herb Pharmacother 4: 21-33.
53. Wu X, Dai H, Huang L, Gao X, Tsim KW, et al. (2006) A fructan, from Radix Ophiopogonis, stimulates the proliferation of cultured lymphocytes: structural and functional analyses. J Nat Products 69: 1257-1260.
54. Roh SS, Kim SH, Lee YC, Seo YB, (2008) Effects of Radix Adenophorae and cyclosporine A on an OVA-induced murine model of asthma by suppressing to T cells activity, eosinophilia, and bronchial hyperresponsiveness. Mediators Inflamm 2008: 781425.
55. Cho WC, Leung KN, (2007) In vitro and in vivo immunomodulating and immune restorative effects of Astragalus membranaceus. J Ethnopharmacol 113: 132-141.
56. Cho WC, Leung KN, (2007) In vitro and in vivo anti-tumor effects of Astragalus membranaceus. Cancer Lett 252: 43-54.
57. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, et al. (2006) Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol 24: 419-430.
58. Chang MS, Kim do R, Ko EB, Choi BJ, Park SY, et al. (2009) Treatment with Astragali radix and Angelicae radix enhances erythropoietin gene expression in the cyclophosphamide-induced anemic rat. J Med Food 12: 637-642.
59. Rjiba-Touati K, Ayed-Boussema I, Belarbia A, Azzebi A, Achour A, et al. (2013) Protective effect of recombinant human erythropoeitin against cisplatin cytotoxicity and genotoxicity in cultured Vero cells. Exp Toxicol Pathol 65: 181-187.
60. Li J, Vesey DA, Johnson DW, Gobe G, (2007) Erythropoietin reduces cisplatin-induced apoptosis in renal carcinoma cells via a PKC dependent pathway. Cancer Biol Ther 6: 1944-1950.
61. Kim W, Kim SH, Park SK, Chang MS, (2012) Astragalus membranaceus ameliorates reproductive toxicity induced by cyclophosphamide in male mice. Phytother Res 26: 1418-1421.
62. Yates JW, Chalmer B, McKegney FP, (1980) Evaluation of patients with advanced cancer using the Karnofsky performance status. Cancer 45: 2220-2224.
63. Glare P, (2005) Clinical predictors of survival in advanced cancer. J Support Oncol 3: 331-339.
64. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, et al. (2012) Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 140: 550-554.